Skip to main content
Premium Trial:

Request an Annual Quote

Not This Time

The first human stem-cell based drug failed two late-stage clinical trials, reports the New York Times. The drug, Prochymal, from Osiris Therapeutics was made from mesenchymal stem cells from healthy young adults and was found to be no more effective than placebo in treating graft-versus-host disease. Prochymal did, however, appear to have an effect in a subset of patients. "Prochymal is having a clear effect in the liver, and that is the most underserved patient population," CEO C. Randal Mills says.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.